enzh-TWfrdeitjaptrues

The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia Web site is intended to provide general information about the program, its care and research programs, and about Waldenstrom's Macroglobulinemia and related diseases. This site also provides links to health information that may be written by Dana-Farber staff or by outside providers, and access (links) to some external Web sites for your convenience. The Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible for the availability, accuracy, or content of these external sites, nor does it endorse them.

No Medical Advice Given
This site is not an attempt to practice medicine or provide specific medical advice, nor does the use of the site establish a doctor-patient relationship. For medical treatment or answers to personal questions, we strongly encourage you to consult with a qualified health care provider. For advice about your own care, please ask your doctor!

Restrictions on Use
You assume full responsibility for using the information on this site, and you understand and agree that the Dana-Farber Waldenstrom's Macroglobulinemia Program is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose. The Dana-Farber Waldenstrom's Macroglobulinemia Program also does not warrant that access to the site will be error- or virus-free.

Copyright Infringement
Material on the Dana-Farber Waldenstrom's Macroglobulinemia Program Web site is protected by copyright law. Unless otherwise stated, users may print or download information from this site for personal, non-commercial use only. Permission to reprint or otherwise reproduce any document in whole or in part is prohibited, unless prior written consent is obtained from the copyright owner.

Latest Bing Center News

Dana-Farber Researchers Use Machine Learning to Understand Rare Familial Blood Cancer

Dana-Farber Researchers Use Machine Learning to Understand Rare Familial Blood Cancer

Researchers at Dana-Farber have put together a data atlas that includes a range of genomic, transcriptomic, epigenetic, and clinical data from patients and healthy donors to try to understand familial WM.

Read more..

Topics from the 11th IWWM Workshop in Madrid

Topics from the 11th IWWM Workshop in Madrid

Bing Center WM experts discuss various topics from the 11th IWWM in Madrid.

Read more..

Expert Advice for Newly Diagnosed Waldenström Macroglobulinemia (WM) Patients

Expert Advice for Newly Diagnosed Waldenström Macroglobulinemia (WM) Patients

What should you know if you or a loved one has been diagnosed with Waldenström macroglobulinemia (WM)? Dr. Shayna Sarosiek of the Dana-Farber Cancer Institute shares key advice.

Read more..

Talking with your Waldenstrom's Macroglobulinemia Patients

Talking with your Waldenstrom's Macroglobulinemia Patients

This document, written by Drs. Jorge Castillo and Shayna Sarosiek, provides a reference guide to assist medical professionals in discussions with WM patients. Patients can give this booklet to their PCP, oncologist, or other health care provider in order to help familiarize them with this uncommon disease.

Read more..

2022 ASH Conference Report: Waldenstrom Macroglobulinemia

2022 ASH Conference Report: Waldenstrom Macroglobulinemia

From the 64th ASH Annual Meeting, Jorge Castillo, MD, Clinical Director of the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, updates our Waldenström patient community on important research results presented this year, offers guidance on finding relevant clinical trials, and highlights what to look for in the coming year.

Read more..

RECORDING AVAILABLE - Treatment, Trials, and Hope-For ALL Stages of Disease

RECORDING AVAILABLE - Treatment, Trials, and Hope-For ALL Stages of Disease

RECORDING NOW AVIALABLE! Join IWMF on ZOOM for this very important topic that affects everyone with a WM diagnosis! Dr. Jorge Castillo presents - Treatments, Trials, and Hope – for ALL Stages of Disease. Dr. Castillo is a GLOBAL SPECIALIST IN Waldenstrom's Macroglobulinemia (WM) AND Clinical Director of the Bing Center Clinic (for WM) at Dana-Farber Cancer Institute.

Read more..

Everything You Want to Know About BTK Inhibitors, Do's and Don'ts

Everything You Want to Know About BTK Inhibitors, Do's and Don'ts

With so many patients choosing BTK inhibitors for their Waldenstrom Macroglobulinemia treatment, and new WM treatments in development, it is difficult to keep up with so much new information. This is your chance to get Dr. Jorge Castillo's expert info about BTK inhibitors, long term goals and monitoring; what to do, what not to do; complications; and even some success stories.

Read more..

Bing Center Researchers Awarded Over $1M in Funding From IWMF

Bing Center Researchers Awarded Over $1M in Funding From IWMF

IWMF grant funding for research projects has helped to provide an understanding of the basic biology and genetics of WM. This research in turn has played a significant role in the development of treatments and treatment guidelines in current use, as well as potential new drugs still in the pipeline. The goal of our research program is to improve quality of life for WM patients and, ultimately, discover a cure.

Read more..

Diagnosis and Management of Waldenstrom’s Macroglobulinemia

Diagnosis and Management of Waldenstrom’s Macroglobulinemia

Waldenstrom’s macroglobulinemia (WM) is a rare type of cancer that begins in the white blood cells.The abnormal white blood cells produce a protein that accumulates in the blood, impairs circulation and causes complications. It continues to be a clinical challenge for treating physicians as complete remissions and prevention of relapse are few in spite of all the therapeutic tools that are currently available.  Besides treatment aspects, correct diagnosis of WM often poses a challenge.

Read more..

U.S. News & World Report Names Dana-Farber Brigham Cancer Center among nation's best for 2022-2023

U.S. News & World Report Names Dana-Farber Brigham Cancer Center among nation's best for 2022-2023

For the 22nd consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report. This year, Dana-Farber Brigham Cancer Center is ranked as the best hospital for cancer care in New England and #4 in the nation.

Read more..